8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  June 5, 2004

IMCLONE SYSTEMS INCORPORATED

(Exact name of Registrant as Specified in Charter)

Delaware	0-19612	04-2834797
(State of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
180 Varick Street, 6th Floor New York, New York 10014
(Address of Principal Executive Offices) (Zip Code)
(212) 645-1405
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)

Item 5.Other Events and Required FD Disclosure

ImClone Systems Incorporated (the “Company”) issued various joint press releases with Bristol-Myers Squibb Company and Merck KGaA, Darmstadt, Germany, in connection with data presented at the Annual Meeting of the American Society of Clinical Oncology held June 5-8, 2004.  The press releases announced (1) the results of a Phase III study of ERBITUX™ (Cetuximab) and high-dose radiation in locally advanced head and neck cancer, (2) a summary of scientific data evaluating ERBITUX in colorectal cancer, (3) the results of a Phase III trial of the Company’s BEC2 cancer vaccine in patients with small cell lung carcinoma, (4) a summary of scientific data evaluating ERBITUX in advanced non-small-cell lung cancer, and (5) a summary of scientific data evaluating ERBITUX in head and neck cancer.

Copies of the press releases are attached hereto as exhibits and incorporated herein by reference.

Item 7.Financial Statements, Pro Forma Financial Information and Exhibits

(c)Exhibits

Exhibit No.	Exhibit Title
99.1	Press release of ImClone Systems Incorporated dated June 5, 2004.
99.2	Press release of ImClone Systems Incorporated dated June 6, 2004.
99.3	Press release of ImClone Systems Incorporated dated June 7, 2004.
99.4	Press release of ImClone Systems Incorporated dated June 7, 2004.
99.5	Press release of ImClone Systems Incorporated dated June 8, 2004.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMCLONE SYSTEMS INCORPORATED
By:	/s/ Clifford R. Saffron
	Name:	Clifford R. Saffron
	Title:	Senior Vice President, Legal and General Counsel

Date:  June 14, 2004

3

EXHIBIT INDEX

Exhibit No.	Exhibit Title
99.1	Press release of ImClone Systems Incorporated dated June 5, 2004.
99.2	Press release of ImClone Systems Incorporated dated June 6, 2004.
99.3	Press release of ImClone Systems Incorporated dated June 7, 2004.
99.4	Press release of ImClone Systems Incorporated dated June 7, 2004.
99.5	Press release of ImClone Systems Incorporated dated June 8, 2004.

4

EX-99.1

Exhibit 99.1

PHASE III STUDY OF ERBITUX™ (Cetuximab) AND HIGH-DOSE RADIATION IN
LOCALLY ADVANCED HEAD AND NECK CANCER PRESENTED AT ASCO

NEW ORLEANS, June 5, 2004 — ImClone Systems Incorporated (Nasdaq: IMCL), Merck KGaA, Darmstadt, Germany (Frankfurt Stock Exchange: MRK), and Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of an international, randomized phase III study of 424 patients with locally advanced squamous cell carcinoma of the head and neck evaluating the addition of ERBITUX™ (Cetuximab) Injection, an IgG1 monoclonal antibody, to high-dose radiation.  The study met both its primary endpoint of locoregional control and its secondary endpoint of overall survival.  This study was presented today at a press conference during the American Society of Clinical Oncology (ASCO) 40^th Annual Meeting.

The percentage of patients who achieved locoregional control at one year and at two years following treatment was 69% and 56% in ERBITUX-treated patients compared to 59% and 48% for those treated with radiation alone.  Likewise, the percentage of patients alive at two and three years post-treatment was 62% and 57% for the ERBITUX-treated patients versus 55% and 44% for those treated with radiation alone.  Both the duration of locoregional control and the duration of survival were statistically significant (log-rank p-value=0.02 for both endpoints).  With a minimum follow-up of 24 months and a median follow-up of 38 months, the median overall survival for the ERBITUX-treated patients was 54 months (95% CI: 36-58+) compared to 28 months (95% CI: 21-38) for patients treated with radiation alone.

The incidence of grade 3/4 mucositis (inflammation of the mucous membrane), a serious adverse event associated with high-dose radiation therapy for head and neck cancer, was similar in both treatment groups (55% in patients receiving radiation plus ERBITUX and 52% in patients who received radiation alone).  Three percent of patients in the radiation plus ERBITUX arm and zero percent of patients in the radiation-alone arm experienced grade 3/4 infusion reactions, and grade 3/4 skin reaction occurred in 34 percent of patients receiving radiation plus ERBITUX compared to 18 percent of radiation-alone patients.

The phase III trial (IMCL-9815) examined the impact of combining ERBITUX with high-dose radiation on locoregional disease control and overall survival in 424 patients with advanced squamous cell carcinoma of the oropharynx (area of the throat at the back of the mouth), larynx (voice box) or hypopharynx (cavity at the back of the mouth that opens into the esophagus) that has spread through the head and neck region.  Patients were randomized to receive radiation plus weekly ERBITUX therapy (n=211) or radiation alone (n=213) for six to seven weeks.

The companies plan to discuss these findings and other head and neck cancer clinical data with the Food and Drug Administration (FDA), as well as the European Medicines Agency (EMEA).

ERBITUX^TM (Cetuximab) Approved Indication

ERBITUX is approved by the FDA for use in combination with irinotecan in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy.  The effectiveness of ERBITUX for the treatment of colorectal cancer is based on objective response rates.  Currently, no data are available that demonstrate an improvement in disease-related symptoms or increased survival with ERBITUX.

Outside the U.S., Merck KGaA, Darmstadt, Germany, gained approval for use of ERBITUX in combination with irinotecan in patients with EGFR-expressing metastatic colorectal cancer who have failed prior irinotecan therapy in Switzerland in December 2003, with EU approval expected in June 2004.

In May 2004, Merck KGaA also received approval for ERBITUX in Argentina and Mexico for use in combination with irinotecan or as a single agent in patients with EGFR-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy.

ERBITUX Important Safety Information

Severe infusion reactions, rarely fatal and characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, and hypotension, have occurred (3%) with the administration of ERBITUX.  Most reactions (90%) are associated with the first infusion of ERBITUX despite the use of prophylactic antihistamines.

Severe cases of interstitial lung disease (ILD), which was fatal in one case, occurred in less than 0.5% of patients receiving ERBITUX.

Dermatologic toxicities, including acneform rash (12% grade 3-4), skin drying and fissuring, and inflammatory or infectious sequelae (e.g. blepharitis, cheilitis, cellulitis, cyst) were reported.  Sun exposure may exacerbate these effects.

Other serious adverse events associated with ERBITUX in clinical trials were fever (5%), sepsis (3%), kidney failure (2%), pulmonary embolus (1%), dehydration (5% in patients receiving ERBITUX plus irinotecan, 2% receiving monotherapy) and diarrhea (6% in patients receiving ERBITUX plus irinotecan, 0% with monotherapy).

Additional common adverse events seen in patients receiving ERBITUX plus irinotecan (n=354) or ERBITUX monotherapy (n=279) were acneform rash (88%/90%), asthenia/malaise (73%/49%), diarrhea (72%/28%), nausea (55%/29%), abdominal pain (45%/25%), vomiting (41%/25%), fever (34%/33%) and constipation (30%/28%).

Full prescribing information is available upon request, or at www.ERBITUX.com.

Background Information

ERBITUX binds specifically to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.  The EGFR is constitutively expressed in many normal epithelial tissues, including the skin and hair follicle.  Over-expression of EGFR is also detected in many human cancers including those of the colon and rectum.

According to the American Cancer Society, approximately 40,000 Americans will be diagnosed with oral, head and neck cancer this year, including cancers of the tongue, mouth, pharynx, and larynx.  More than

11,000 will die from the disease in 2004.  Approximately 70,000 new cases are diagnosed annually in Europe, with more than 25,000 deaths each year.  Treatment for head and neck cancer may include surgery, radiation therapy and chemotherapy or some combination of these.

About ImClone Systems Incorporated

ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company’s three programs include growth factor blockers, angiogenesis inhibitors and cancer vaccines. ImClone Systems’ strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems’ headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company’s ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company’s filings with the Securities and Exchange Commission including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists at Bristol-Myers Squibb’s Pharmaceutical Research Institute are studying ways to improve current cancer treatments and identify better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development.  Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed.  Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2003 and in our Quarterly Reports on Form 10-Q.  Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a global pharmaceutical and chemical company with sales of EUR 7.2 billion in 2003, a history that began in 1668, and a future shaped by 28,300 employees in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 74 percent interest and free shareholders own the remaining 26 percent. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917.

Merck KGaA, Darmstadt, Germany, licensed the right to market ERBITUX outside the U.S. and Canada from ImClone Systems Incorporated of New York in 1998.  In Japan, Merck KGaA has co-exclusive marketing rights with ImClone Systems.

# # #

Note to editors:

Results of IMC-9815 (Abstract 5507) were presented Saturday, June 5, 8:00 AM CDT during a press conference on aerodigestive cancers sponsored by the American Society of Clinical Oncology (ASCO).  Data will be presented to conference attendees Tuesday, June 8, 10:30 AM CDT during an oral presentation session on head and neck cancer.

Media and Investor Contacts:

Andrea Rabney Corporate Communications ImClone Systems Incorporated Tel: (646) 638-5058 Andrea.Rabney@imclone.com	Tracy Furey Corporate Affairs Bristol-Myers Squibb Tel: (609) 252-3208 Tracy.Furey@bms.com	Susan Walser Investor Relations Bristol-Myers Squibb Tel: (212) 546-4631 Susan.walser@bms.com
or
David Pitts Corporate Communications ImClone Systems Incorporated Tel: (646) 638-5058 David.Pitts@imclone.com	Kathy Baum Corporate Affairs Bristol-Myers Squibb Tel: (609) 252-4227 Kathy.Baum@bms.com	John Elicker Investor Relations Bristol-Myers Squibb Tel: (212) 546-3775 john.elicker@bms.com
or
Stefania Bethlen Corporate Communications/IR ImClone Systems Incorporated Tel: (646) 638-5058 Stefania.Bethlen@imclone.com	Phyllis Carter Corporate Media Relations Merck KGaA Tel.: +49 6151 72 7144 Phyllis.Carter@merck.de

EX-99.2

Exhibit 99.2

SCIENTIFIC DATA PRESENTED AT ASCO ANNUAL MEETING
EVALUATING ERBITUX ^TM (Cetuximab) IN COLORECTAL CANCER

NEW ORLEANS, June 6, 2004 – ImClone Systems Incorporated (Nasdaq: IMCL), Merck KGaA, Darmstadt, Germany (Frankfurt Stock Exchange: MRK), and Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of four clinical studies of ERBITUX^Ô(Cetuximab) Injection, an IgG1 monoclonal antibody, in various lines of treatment, in combination with multiple chemotherapy agents, including irinotecan and oxaliplatin, and as a single agent in the treatment of Epidermal Growth Factor Receptor (EGFR)-expressing metastatic colorectal cancer (CRC).  These new data were presented at the American Society of Clinical Oncology (ASCO) 40^th Annual Meeting.

Investigators who conducted the four studies of ERBITUX for metastatic CRC presented the following data:

Abstract #3510

Response rate and median overall survival results were presented from a Phase II study (IMCL-0144) of 346 patients with EGFR-expressing CRC that were refractory to chemotherapy with irinotecan and oxaliplatin.  Patients received standard doses of ERBITUX as monotherapy.  Data from an independent review demonstrated that 11.6 percent (95% CI: 8-17) of patients had a partial response, 31.8 percent experienced stable disease for at least six weeks, 46.8 percent had progressive disease, and 9.8 percent were not evaluable.  Median overall survival was 6.7 months (95% CI: 5.9-7.8).

The most common adverse events were acne-like skin rash (90%; grade 3/4, 6%) and fatigue/malaise (48%; grade 3/4, 10%).  One patient experienced a grade 3 infusion reaction requiring discontinuation of therapy.

Abstract #3513

A phase I/II trial (EMR-010) conducted by Merck KGaA was designed to determine a safe dose for the combination of ERBITUX and FOLFIRI (irinotecan/infusional 5-FU/folinic acid), or ERFLIRI, as first-line treatment in 52 patients with EGFR-expressing metastatic CRC.  Patients received ERBITUX plus high-dose FOLFIRI (n=42) or low-dose FOLFIRI (n=10).  Based on preliminary results, the safety profile of high-dose FOLFIRI was considered acceptable.

Of the 40 high-dose patients evaluable for efficacy, 43 percent (95% CI: 27-59) had a partial response, 45 percent (95% CI: 29-62) experienced stable disease and 12 percent (95% CI: 4-27) experienced progressive disease.  Five patients underwent secondary surgery of metastases.

Of the 42 patients in the high-dose group evaluable for safety, the most frequent grade 3/4 adverse events were leucopenia (17%), diarrhea (14%), vomiting (11%), rash (7%) and asthenia (7%).

Abstract #3512

A phase II study conducted by Merck KGaA (EMR-018) evaluated the effect on overall response of ERBITUX and FOLFOX-4 (oxaliplatin/5-FU/folinic acid), or ERFLOX, as first-line treatment in patients with EGFR-expressing metastatic CRC.  In a preliminary analysis of 42 evaluable patients, 5 percent (95% CI: 1-16) had complete response, 76 percent (95% CI: 61-88) had a partial response, 17 percent (95% CI: 7-32) experienced stable disease, and 2 percent (95% CI: 1-13) experienced progressive disease.

The major grade 3/4 toxicities in 43 patients evaluable for safety were diarrhea (26%), acne-like rash (21%) and neutropenia (14%).

Abstract #3531

In the preliminary safety analysis of 40 patients in a phase III trial (BMS-014 or EXPLORE), patients were randomized to either Arm A (ERBITUX and FOLFOX-4) or to Arm B (FOLFOX-4) as second-line therapy following progression on first line with irinotecan.  Only patients with metastatic EGFR-expressing colorectal cancer were eligible.  The study was designed to evaluate the effect of the addition of ERBITUX to standard FOLFOX chemotherapy on overall survival.

Of the 38 evaluable patients in the pooled population (Arm A + Arm B), the most frequent adverse events of any grade were neuropathy (68%), nausea (63%), asthenia (50%; grade 3, 5%), diarrhea (47%; grade 3, 5%), vomiting (34%; grade 3, 3%) and skin toxicity (42%; grade 3, 3%).  One patient discontinued therapy due to a serious nonfatal infusion reaction (grade 4).  Based on these data, the companies plan to continue enrollment in the trial, which will study the effect of the addition of ERBITUX to FOLFOX on survival in second-line CRC.

ERBITUX^TM (Cetuximab) Approved Indication

ERBITUX is approved by the FDA for use in combination with irinotecan in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy.  The effectiveness of ERBITUX for the treatment of colorectal cancer is based on objective response rates.  Currently, no data are available that demonstrate an improvement in disease-related symptoms or increased survival with ERBITUX.

Outside the U.S., Merck KGaA, Darmstadt, Germany, gained approval for use of ERBITUX in combination with irinotecan in patients with EGFR-expressing metastatic colorectal cancer who have failed prior irinotecan therapy in Switzerland in December 2003, with EU approval expected in June 2004.

In May 2004, Merck KGaA also received approval for ERBITUX in Argentina and Mexico for use in combination with irinotecan or as a single agent in patients with EGFR-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy.

ERBITUX Important Safety Information

Severe infusion reactions, rarely fatal and characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, and hypotension, have occurred (3%) with the administration of ERBITUX.  Most reactions (90%) are associated with the first infusion of ERBITUX, despite the use of prophylactic antihistamines.

Severe cases of interstitial lung disease (ILD), which was fatal in one case, occurred in less than 0.5% of patients receiving ERBITUX.

Dermatologic toxicities, including acneform rash (12% grade 3-4), skin drying and fissuring, and inflammatory or infectious sequelae (e.g. blepharitis, cheilitis, cellulitis, cyst) were reported.  Sun exposure may exacerbate these effects.

Other serious adverse events associated with ERBITUX in clinical trials were fever (5%), sepsis (3%), kidney failure (2%), pulmonary embolus (1%), dehydration (5% in patients receiving ERBITUX plus irinotecan, 2% receiving monotherapy) and diarrhea (6% in patients receiving ERBITUX plus irinotecan, 0% with monotherapy).

Additional common adverse events seen in patients receiving ERBITUX™ plus irinotecan (n=354) or ERBITUX monotherapy (n=279) were acneform rash (88%/90%), asthenia/malaise (73%/49%), diarrhea (72%/28%), nausea (55%/29%), abdominal pain (45%/25%), vomiting (41%/25%), fever (34%/33%) and constipation (30%/28%).

Full prescribing information is available upon request, or at www.ERBITUX.com.

Background Information

ERBITUX binds specifically to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.  The EGFR is constitutively expressed in many normal epithelial tissues, including the skin and hair follicle.  Over-expression of EGFR is also detected in many human cancers including those of the colon and rectum.

In the U.S., approximately 147,000 people will be diagnosed with cancer of the colon or rectum this year.  Half of these patients have metastatic disease, or cancer that has spread to other organs, at the time of diagnosis.  EGFR is expressed in up to 77 percent of colorectal cancer tumors.  Colorectal cancer is the second-leading cause of cancer death in the U.S.

About ImClone Systems Incorporated

ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company’s three programs include growth factor blockers, angiogenesis inhibitors and cancer vaccines. ImClone Systems’ strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems’ headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company’s ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company’s filings with the Securities and Exchange Commission including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists at Bristol-Myers Squibb’s Pharmaceutical Research Institute are studying ways to improve current cancer treatments and identify better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development.  Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed.  Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2003 and in our Quarterly Reports on Form 10-Q.  Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a global pharmaceutical and chemical company with sales of EUR 7.2 billion in 2003, a history that began in 1668, and a future shaped by 28,300 employees in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 74 percent interest and free shareholders own the remaining 26 percent. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917.

Merck KGaA, Darmstadt, Germany, licensed the right to market ERBITUX outside the U.S. and Canada from ImClone Systems Incorporated of New York in 1998.  In Japan, Merck KGaA has co-exclusive marketing rights with ImClone Systems.

# # #

Note to editors:

Data from BMS-014 (Abstract 3531) were presented Saturday, June 5, 1:00 PM CDT during a general poster session on gastrointestinal (colorectal) cancer.

Data from EMR-010 (Abstract 3513), EMR-018 (Abstract 3512) and IMCL-0144 (Abstract 3510) were presented Sunday, June 6, 8:00 AM CDT during a poster discussion session on gastrointestinal (colorectal) cancer.

Media and Investor Contacts:

Andrea Rabney Corporate Communications ImClone Systems Incorporated Tel: (646) 638-5058 Andrea.Rabney@imclone.com	Tracy Furey Corporate Affairs Bristol-Myers Squibb Tel: (609) 252-3208 Tracy.Furey@bms.com	Susan Walser Investor Relations Bristol-Myers Squibb Tel: (212) 546-4631 Susan.walser@bms.com
or
David Pitts Corporate Communications ImClone Systems Incorporated Tel: (646) 638-5058 David.Pitts@imclone.com	Kathy Baum Corporate Affairs Bristol-Myers Squibb Tel: (609) 252-4227 Kathy.Baum@bms.com	John Elicker Investor Relations Bristol-Myers Squibb Tel: (212) 546-3775 john.elicker@bms.com
or
Stefania Bethlen Corporate Communications/IR ImClone Systems Incorporated Tel: (646) 638-5058 Stefania.Bethlen@imclone.com	Phyllis Carter Corporate Media Relations Merck KGaA Tel.: +49 6151 72 7144 Phyllis.Carter@merck.de

EX-99.3

Exhibit 99.3

IMC-BEC2 CANCER VACCINE DID NOT MEET PRIMARY ENDPOINT IN PHASE III CLINICAL TRIAL IN PATIENTS WITH SMALL CELL LUNG CARCINOMA

NEW ORLEANS — June 7, 2004 — ImClone Systems Incorporated (NASDAQ: IMCL) and Merck KGaA of Darmstadt, Germany (Frankfurt Stock Exchange: MRK), announced today that the international, randomized Phase III clinical trial of the Companies’ IMC-BEC2 cancer vaccine did not meet its primary endpoint of survival. IMC-BEC2 is an investigational anti-idiotypic monoclonal antibody that mimics GD3, a ganglioside expressed on the cell membrane of most small cell lung cancer (SCLC) tumors. The study was conducted in collaboration with the cooperative group European Organisation for Research and Treatment of Cancer (EORTC). The results of the clinical trial were presented today by EORTC investigator Giuseppe Giaccone, MD, PhD, Department of Oncology, Free University Medical Center, Amsterdam, in a presentation at the American Society of Clinical Oncology annual meeting.

The clinical trial was designed to assess the survival benefit of vaccination with IMC-BEC2 and the immune stimulant BCG over a two-year period. Patients in the trial were randomized into either the treatment arm, receiving IMC-BEC2/BCG vaccination, or into the observation arm.

“Given the limited success with cancer vaccines in the recent past, we were disappointed, but appreciate that there has been limited success with cancer vaccines in the recent past,” stated Daniel S. Lynch, Chief Executive Officer of ImClone Systems. “The conduct of clinical trials to further the treatment of cancer, regardless of their outcome, takes a tremendous commitment from the oncology community and from the courageous patients who participate. ImClone Systems remains steadfast to this commitment.”

“We would especially like to thank the co-operative study groups and the patients who participated in the trial for their commitment,” added Dr. Bernhard Ehmer, Vice President Business Area Oncology, Merck KGaA.

The Companies intend to meet in the near-term to discuss the ongoing viability of the IMC-BEC2 development program.

About ImClone Systems Incorporated

ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company’s three programs include growth factor blockers, angiogenesis inhibitors and cancer vaccines. ImClone Systems’ strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research

stage to the market. ImClone Systems’ headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company’s ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company’s filings with the Securities and Exchange Commission including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a global pharmaceutical and chemical company with sales of EUR 7.2 billion in 2003, a history that began in 1668, and a future shaped by 28,300 employees in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 74 percent interest and free shareholders own the remaining 26 percent. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917.

Media and Investor Contacts:

Andrea Rabney Corporate Communications ImClone Systems Incorporated Tel: (646) 638-5058 Andrea.Rabney@imclone.com	Stefania Bethlen Corporate Communications/IR ImClone Systems Incorporated Tel: (646) 638-5058 Stefania.Bethlen@imclone.com
or
David Pitts Corporate Communications ImClone Systems Incorporated Tel: (646) 638-5058 David.Pitts@imclone.com	Phyllis Carter Corporate Media Relations Merck KGaA Tel.: +49 6151 72 7144 Phyllis.Carter@merck.de

EX-99.4

Exhibit 99.4

SCIENTIFIC DATA PRESENTED AT ASCO ANNUAL MEETING

EVALUATING ERBITUX ^TM (Cetuximab) IN ADVANCED

NON-SMALL-CELL LUNG CANCER

NEW ORLEANS, June 7, 2004 – ImClone Systems Incorporated (Nasdaq: IMCL), Merck KGaA, Darmstadt, Germany (Frankfurt Stock Exchange: MRK), and Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of two clinical studies of ERBITUX™ (Cetuximab) Injection, an IgG1 monoclonal antibody, in combination with standard chemotherapy in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) and as a single agent in the treatment of patients with late-stage recurrent or metastatic NSCLC who have exhausted other treatment options.  These new data were presented at the American Society of Clinical Oncology (ASCO) 40^th Annual Meeting.

Abstract #7012

A randomized phase II study (EMR-011 or LUCAS) conducted by Merck KGaA examined the addition of ERBITUX to standard chemotherapy with cisplatin and vinorelbine as first-line treatment of Epidermal Growth Factor Receptor (EGFR)-expressing advanced NSCLC compared to treatment with cisplatin and vinorelbine alone.  The primary endpoint was objective response rate.

Of 43 patients receiving ERBITUX plus chemotherapy, 35 percent (95% CI: 21-51) experienced a confirmed response (54% including unconfirmed response). Of 43 patients receiving chemotherapy alone, 28 percent (95% CI: 15-44) experienced a confirmed response (33% including unconfirmed response).  Overall rate of disease control, defined as partial response plus stable disease, was 84 percent in the ERBITUX plus chemotherapy group versus 68 percent in the chemotherapy-alone group.

Median progression-free survival in the ERBITUX plus chemotherapy group was 4.8 months (95% CI: 3.3-5.8) versus 4.2 months (95% CI: 2.5-5.0) in the chemotherapy-alone group.  Median survival time was 8.3 months (95% CI: 6.1-9.9) in the ERBITUX group and 7 months (95% CI: 5.6-9.5) in the chemotherapy-alone group.

Commonly occurring grade 3/4 adverse events in the ERBITUX plus chemotherapy arm compared to the chemotherapy-only arm were leucopenia (50% vs. 37%; grade 4, 10% vs. 10%), asthenia/fatigue (19% vs. 2%), nausea/vomiting (17% vs. 14%), skin reaction (12% vs. 0%), fever/chills (10% vs. 5%), infection (5% vs. 2%) and thrombocytopenia (5% vs. 2%).

Abstract #7084

A phase II trial (BMS-012) examined response rates in patients with stage IIIB/IV NSCLC who had recurrent or metastatic disease following one or more prior regimens of chemotherapy, including prior platinum-based chemotherapy.  Patients received standard therapy with ERBITUX until disease progression or the development of unacceptable toxicity.

At a planned interim analysis of 33 patients with EGFR-expressing NSCLC enrolled in the trial, 6 percent experienced partial responses, 21 percent had stable disease and 73 percent had progressive disease.

Forty-nine patients were evaluable for toxicity.  Grade 3/4 adverse events that may have been related to therapy were asthenia/malaise (12.2%), acneform rash (4.1%), infusion reaction (2%) and nausea/vomiting (2%).

ERBITUX^TM (Cetuximab) Approved Indication

ERBITUX is approved by the FDA for use in combination with irinotecan in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy.  The effectiveness of ERBITUX for the treatment of colorectal cancer is based on objective response rates.  Currently, no data are available that demonstrate an improvement in disease-related symptoms or increased survival with ERBITUX.

Outside the U.S., Merck KGaA, Darmstadt, Germany, gained approval for use of ERBITUX in combination with irinotecan in patients with EGFR-expressing metastatic colorectal cancer who have failed prior irinotecan therapy in Switzerland in December 2003, with EU approval expected in June 2004.

In May 2004, Merck KGaA also received approval for ERBITUX in Argentina and Mexico for use in combination with irinotecan or as a single agent in patients with EGFR-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy.

ERBITUX Important Safety Information

Severe infusion reactions, rarely fatal and characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, and hypotension, have occurred (3%) with the administration of ERBITUX.  Most reactions (90%) are associated with the first infusion of ERBITUX despite the use of prophylactic antihistamines.

Severe cases of interstitial lung disease (ILD), which was fatal in one case, occurred in less than 0.5% of patients receiving ERBITUX.

Dermatologic toxicities, including acneform rash (12% grade 3-4), skin drying and fissuring, and inflammatory or infectious sequelae (e.g. blepharitis, cheilitis, cellulitis, cyst) were reported.  Sun exposure may exacerbate these effects.

Other serious adverse events associated with ERBITUX in clinical trials were fever (5%), sepsis (3%), kidney failure (2%), pulmonary embolus (1%), dehydration (5% in patients receiving ERBITUX plus irinotecan, 2% receiving monotherapy) and diarrhea (6% in patients receiving ERBITUX plus irinotecan, 0% with monotherapy).

Additional common adverse events seen in patients receiving ERBITUX plus irinotecan (n=354) or ERBITUX monotherapy (n=279) were acneform rash (88%/90%), asthenia/malaise (73%/49%), diarrhea (72%/28%), nausea (55%/29%), abdominal pain (45%/25%), vomiting (41%/25%), fever (34%/33%) and constipation (30%/28%).

Full prescribing information is available upon request, or at www.ERBITUX.com.

Background Information

ERBITUX binds specifically to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.  The EGFR is constitutively expressed in many

normal epithelial tissues, including the skin and hair follicle.  Over-expression of EGFR is also detected in many human cancers including those of the colon and rectum.

According to the American Cancer Society, more than 173,000 Americans will be diagnosed with lung cancer this year, and more than 160,000 will die from the disease.  Lung cancer is the leading cause of cancer deaths.

About ImClone Systems Incorporated

ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.  The Company’s three programs include growth factor blockers, angiogenesis inhibitors and cancer vaccines.  ImClone Systems’ strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market.  ImClone Systems’ headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws.  Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved.  Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected.  Many of these factors are beyond the company’s ability to control or predict.  Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company’s filings with the Securities and Exchange Commission including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K.  For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer.  More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment.  With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today.  Hundreds of scientists at Bristol-Myers Squibb’s Pharmaceutical Research Institute are studying ways to improve current cancer treatments and identify better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development.  Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed.  Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2003 and in our

Quarterly Reports on Form 10-Q.  Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a global pharmaceutical and chemical company with sales of EUR 7.2 billion in 2003, a history that began in 1668, and a future shaped by 28,300 employees in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 74 percent interest and free shareholders own the remaining 26 percent. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917.

Merck KGaA, Darmstadt, Germany, licensed the right to market ERBITUX outside the U.S. and Canada from ImClone Systems Incorporated of New York in 1998.  In Japan, Merck KGaA has co-exclusive marketing rights with ImClone Systems.

# # #

Note to editors:

Data from BMS-012 (Abstract 7084) were presented Saturday, June 5, 8:00 AM CDT during a general poster session on lung cancer.

Data from EMR-011 (Abstract 7012) were presented Monday, June 7, 10:00 AM CDT during an oral presentation session on lung cancer.

Media and Investor Contacts:

Andrea Rabney Corporate Communications ImClone Systems Incorporated Tel: (646) 638-5058 Andrea.Rabney@imclone.com	Tracy Furey Corporate Affairs Bristol-Myers Squibb Tel: (609) 252-3208 Tracy.Furey@bms.com	Susan Walser Investor Relations Bristol-Myers Squibb Tel: (212) 546-4631 Susan.walser@bms.com
or
David Pitts Corporate Communications ImClone Systems Incorporated Tel: (646) 638-5058 David.Pitts@imclone.com	Kathy Baum Corporate Affairs Bristol-Myers Squibb Tel: (609) 252-4227 Kathy.Baum@bms.com	John Elicker Investor Relations Bristol-Myers Squibb Tel: (212) 546-3775 john.elicker@bms.com
or
Stefania Bethlen Corporate Communications/IR ImClone Systems Incorporated Tel: (646) 638-5058 Stefania.Bethlen@imclone.com	Phyllis Carter Corporate Media Relations Merck KGaA Tel.: +49 6151 72 7144 Phyllis.Carter@merck.de

EX-99.5

Exhibit 99.5

SCIENTIFIC DATA PRESENTED AT ASCO ANNUAL MEETING
EVALUATING ERBITUX^TM (Cetuximab) IN HEAD AND NECK CANCER

NEW ORLEANS, June 8, 2004 – ImClone Systems Incorporated (Nasdaq: IMCL),Merck KGaA, Darmstadt, Germany (Frankfurt Stock Exchange: MRK), and Bristol-Myers Squibb Company (NYSE: BMY) today announced the findings of two Merck KGaA-sponsored studies of ERBITUX^™ (Cetuximab) Injection, an IgG1 monoclonal antibody, in patients with advanced squamous cell carcinoma of the head and neck (SCCHN), as presented at the American Society of Clinical Oncology (ASCO) 40^th Annual Meeting.  The studies assessed ERBITUX as a single agent in patients with platinum-refractory advanced SCCHN and in combination with platinum-based chemotherapy and 5-fluorouracil (5-FU) in patients with recurrent and/or metastatic SCCHN.  The companies plan to discuss these study findings, as well as the previously announced results of a large international Phase III study also presented today (IMCL-9815), with the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA).

Abstract #5502

A multicenter phase II study conducted by Merck KGaA (EMR-016) evaluated the response rate of ERBITUX as a single agent in 103 patients with advanced recurrent and/or metastatic SCCHN not suitable for local therapy and refractory to platinum-based chemotherapy.

Data from an independent review demonstrated an overall response rate of 12.6 percent.  The disease control rate was 45.6 percent (95% CI: 35.8-55.7), which was defined as partial response (12.6%) plus stable disease (33%).  Median time to progression was 2.3 months, median survival was 5.9 months, and median duration of response was 5.9 months.

In 53 patients whose disease progressed during ERBITUX monotherapy who then received ERBITUX in combination with platinum-based chemotherapy, there were 14 patients with stable disease, 14 patients with progressive disease and 25 patients were not assessable.  Median time to progression in this group was 50 days.

The most commonly reported adverse events occurring in more than 20 percent of patients, regardless of relationship to therapy, included acne-like rash (69%; grade 3/4, 1%) and fatigue (24%; grade 3/4, 4%). Additional grade 3/4 adverse events included vomiting (2%), nausea (1%) and diarrhea (1%).  There was one treatment-related death due to infusion reaction.

Abstract #5513

A randomized phase I study conducted by Merck KGaA (EMR-008) evaluated the safety and tolerability of ERBITUX in combination with one of three doses of 5-FU and either cisplatin or carboplatin in 53 patients with recurrent and/or metastatic SCCHN.

An efficacy analysis of the pooled arms demonstrated a disease control rate of 69.8 percent (95% CI: 55.7-81.7), which was defined as complete response plus partial response plus stable disease.  The overall response rate was 35.9 percent (95% CI: 23.1-50.2).  Median time to progression was 155 days (95% CI: 127-186), and median survival was 297 days (95% CI: 242-418).

The most frequent adverse event (any grade) was skin reaction (74%, cisplatin group; 92%, carboplatin group). The most frequent grade 3/4 adverse events in the group receiving cisplatin (n=27) regardless of relationship to study medication were leucopenia (56%), asthenia (33%), nausea/vomiting (26%), mucositis (15%), anemia (15%), thrombocytopenia (11%), diarrhea (7%) and anorexia (4%).  Among patients receiving carboplatin (n=25), the most frequent grade 3/4 adverse events regardless of relationship to study medication were leucopenia (20%), thrombocytopenia (20%), asthenia (16%), mucositis (12%), anemia (8%), acne-like reaction (4%) and skin reaction (4%).

ERBITUX^TM (Cetuximab) Approved Indication

ERBITUX is approved by the FDA for use in combination with irinotecan in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy.  The effectiveness of ERBITUX for the treatment of colorectal cancer is based on objective response rates.  Currently, no data are available that demonstrate an improvement in disease-related symptoms or increased survival with ERBITUX.

Outside the U.S., Merck KGaA, Darmstadt, Germany, gained approval for use of ERBITUX in combination with irinotecan in patients with EGFR-expressing metastatic colorectal cancer who have failed prior irinotecan therapy in Switzerland in December 2003, with EU approval expected in June 2004.

In May 2004, Merck KGaA also received approval for ERBITUX in Argentina and Mexico for use in combination with irinotecan or as a single agent in patients with EGFR-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy.

ERBITUX Important Safety Information

Severe infusion reactions, rarely fatal and characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, and hypotension, have occurred (3%) with the administration of ERBITUX.  Most reactions (90%) are associated with the first infusion of ERBITUX despite the use of prophylactic antihistamines.

Severe cases of interstitial lung disease (ILD), which was fatal in one case, occurred in less than 0.5% of patients receiving ERBITUX.

Dermatologic toxicities, including acneform rash (12% grade 3-4), skin drying and fissuring, and inflammatory or infectious sequelae (e.g. blepharitis, cheilitis, cellulitis, cyst) were reported.  Sun exposure may exacerbate these effects.

Other serious adverse events associated with ERBITUX in clinical trials were fever (5%), sepsis (3%), kidney failure (2%), pulmonary embolus (1%), dehydration (5% in patients receiving ERBITUX plus irinotecan, 2% receiving monotherapy) and diarrhea (6% in patients receiving ERBITUX plus irinotecan, 0% with monotherapy).

Additional common adverse events seen in patients receiving ERBITUX plus irinotecan (n=354) or ERBITUX monotherapy (n=279) were acneform rash (88%/90%), asthenia/malaise (73%/49%), diarrhea (72%/28%), nausea (55%/29%), abdominal pain (45%/25%), vomiting (41%/25%), fever (34%/33%) and constipation (30%/28%).

Full prescribing information is available upon request, or at www.ERBITUX.com.

Background Information

ERBITUX binds specifically to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.  The EGFR is constitutively expressed in many normal epithelial tissues, including the skin and hair follicle.  Over-expression of EGFR is also detected in many human cancers including those of the colon and rectum.

According to the American Cancer Society, approximately 40,000 Americans will be diagnosed with oral, head and neck cancer this year, including cancers of the tongue, mouth, pharynx, and larynx.  More than 11,000 will die from the disease in 2004.  Approximately 70,000 new cases are diagnosed annually in Europe, with more than 25,000 deaths each year.  Treatment for head and neck cancer may include surgery, radiation therapy and chemotherapy or some combination of these.

About ImClone Systems Incorporated

ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company’s three programs include growth factor blockers, angiogenesis inhibitors and cancer vaccines. ImClone Systems’ strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems’ headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey.

Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company’s ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company’s filings with the Securities and Exchange Commission including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists at Bristol-Myers Squibb’s Pharmaceutical Research Institute are studying ways to improve current cancer treatments and identify better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development.  Such forward-looking statements are

based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed.  Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb’s business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2003 and in our Quarterly Reports on Form 10-Q.  Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, is a global pharmaceutical and chemical company with sales of EUR 7.2 billion in 2003, a history that began in 1668, and a future shaped by 28,300 employees in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds a 74 percent interest and free shareholders own the remaining 26 percent. The former U.S. subsidiary, Merck & Co., has been completely independent of the Merck Group since 1917.

Merck KGaA, Darmstadt, Germany, licensed the right to market ERBITUX outside the U.S. and Canada from ImClone Systems Incorporated of New York in 1998.  In Japan, Merck KGaA has co-exclusive marketing rights with ImClone Systems.

# # #

Notes to editors:

Data from EMR-008 (Abstract 5513) were presented Sunday, June 6, 1:00 PM CDT during a poster discussion session on head and neck cancer.

Data from EMR-016 (Abstract 5502) were presented Tuesday, June 8, 10:45 AM CDT during an oral presentation session on head and neck cancer.

Media and Investor Contacts:

Andrea Rabney Corporate Communications ImClone Systems Incorporated Tel: (646) 638-5058 Andrea.Rabney@imclone.com	Tracy Furey Corporate Affairs Bristol-Myers Squibb Tel: (609) 252-3208 Tracy.Furey@bms.com	Susan Walser Investor Relations Bristol-Myers Squibb Tel: (212) 546-4631 Susan.walser@bms.com
or
David Pitts Corporate Communications ImClone Systems Incorporated Tel: (646) 638-5058 David.Pitts@imclone.com	Kathy Baum Corporate Affairs Bristol-Myers Squibb Tel: (609) 252-4227 Kathy.Baum@bms.com	John Elicker Investor Relations Bristol-Myers Squibb Tel: (212) 546-3775 john.elicker@bms.com
or
Stefania Bethlen Corporate Communications/IR ImClone Systems Incorporated Tel: (646) 638-5058 Stefania.Bethlen@imclone.com	Phyllis Carter Corporate Media Relations Merck KGaA Tel.: +49 6151 72 7144 Phyllis.Carter@merck.de